A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–781. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760–62. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760–6
   Google Scholar
• Booth C, Pascoe D. A comparison of newer drug treatments for urinary incontinence. Hospital Pharmacist 2002;9:69–753. Booth C, Pascoe D. A comparison of newer drug treatments for urinary incontinence. Hospital Pharmacist 2002;9:69–75
   Google Scholar
• Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588–954. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588–95
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464–705. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464–70
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17:599–6116. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17:599–611
   PubMed Web of Science ®Google Scholar
• Johannesson M, O'Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997;80:557–627. Johannesson M, O'Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997;80:557–62
   PubMedGoogle Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol Int 2004;93:303–108. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol Int 2004;93:303–10
   Google Scholar
• Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376–849. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376–84
   PubMed Web of Science ®Google Scholar
• Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50 Suppl 6A:100–7 discussion 108–1010. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50 Suppl 6A:100–7 discussion 108–10
   PubMed Web of Science ®Google Scholar
• O'Brien BJ, Goeree R, Bernard L, et al. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001;23:2038–4911. O'Brien BJ, Goeree R, Bernard L, et al. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001;23:2038–49
   PubMed Web of Science ®Google Scholar
• Netten A, Curtis L. Hospital & community health services (HCHS) pay and prices index in unit costs of health and social care. Canterbury (UK): PSSRU Personal Social Services Research Unit; 200412. Netten A, Curtis L. Hospital & community health services (HCHS) pay and prices index in unit costs of health and social care. Canterbury (UK): PSSRU Personal Social Services Research Unit; 2004
   Google Scholar
• Netten A, Curtis L. Unit costs of health and social care. Canterbury (UK): PSSRU Personal Social Services Research Unit; 200513. Netten A, Curtis L. Unit costs of health and social care. Canterbury (UK): PSSRU Personal Social Services Research Unit; 2005
   Google Scholar
• The Continence Foundation. Making the case of investment in an integrated continence service; 200014. The Continence Foundation. Making the case of investment in an integrated continence service; 2000
   Google Scholar
• IMS Health. MIDAS, MAT, 200715. IMS Health. MIDAS, MAT, 2007
   Google Scholar
• Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. Br J Urol Int 2005;95:335–4016. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. Br J Urol Int 2005;95:335–40
   Google Scholar
• Department of Health. Prescription cost analysis 1999 http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalhealthcare/DH_4015574?IdcService=GET_FILE&dID=28768&Rendition=Web17. Department of Health. Prescription cost analysis 1999 http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalhealthcare/DH_4015574?IdcService=GET_FILE&dID=28768&Rendition=Web
   Google Scholar
• Department of Health prescription cost analysis 2006. http://www.ic.nhs.uk/webfiles/publications/pca2006/PCA_2006.pdf18. Department of Health prescription cost analysis 2006. http://www.ic.nhs.uk/webfiles/publications/pca2006/PCA_2006.pdf
   Google Scholar